Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for transdermal administration of gp iib/iiia antagonist

a technology of gp iib and iiia, which is applied in the field of transdermal administration of gp iib/iiia antagonist, can solve the problems of side effects, prolonging bleeding time, and not showing therapeutic efficacy without maintaining a long-term pharmacologically effective serum concentration, so as to reduce the risk of side effects, maintain stable, and excellent pharmacological

Inactive Publication Date: 2001-08-30
HISAMITSU PHARM CO INC
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] The present invention provides a method for transdermal administration of GP IIb / IIIa antagonist by iontophoresis, which method stably maintains the effective serum concentration for a long term, insures expression of excellent pharmacological efficacy with a reduced risk for side effects, and can provide an opportunity of self-administration, in the prophylaxis or therapy of (1) angina pectoris, (2) unstable angina, and (3) reobstruction and restenosis of coronary arteries after PTCA (percutaneous transluminal coronary angioplasty) or coronary thrombolysis.

Problems solved by technology

The first problem is that the serum concentration threshold causing a prolongation of bleeding time, a side effect, is so close to the effective serum concentration range producing the main pharmacological efficacy that the serum concentration of the drug must be somehow controlled so that the main effect may be isolated from the side effect.
The second problem is that therapeutic efficacy is not shown without maintenance of pharmacologically effective serum concentration for a long term (e.g. about not less than 3 days, preferably about 3 to 100 days, more preferably about 7 to 100, further more preferably about 7 to 30 days, most preferably about 7 to 14 days), in view of the operation mechanism of GP IIb / IIIa antagonists.
The third problem is that because of the high hydrophilicity and poor mucosal penetration efficiency of those compounds, their application by the oral route, which is of convenience in self-administration, cannot be expected so that generally intravenous infusion, which is feasible only on an inpatient basis, has so far been the exclusive method of administration which is safe and effective.
The first and second problems suggest that the preferred serum concentration pattern of any GP IIb / IIIa antagonist is such that the drug reaches its therapeutically effective concentration range quickly and maintains that concentration range for a long time.
With regard to the third problem, nasal administration or transpulmonary administration, together with an absorption promoter, may be considered possible as a method enabling self-administration but is not satisfactory in that a transient excessive elevation of serum concentration in an initial phase following administration, which is observed with those administration methods in common, contributes to side effects.
Transdermal administration may be mentioned as another method permitting self-administration but, as far as the conventional transdermal delivery system is concerned, the absorbability of those highly water-soluble compounds is generally very low even when they are formulated with an absorption promoter and other additives so that it cannot be considered to be a realistically useful method of administration.
Supposing that the necessary absorption could be attained by some means or other, the absorption lag time would be too long (generally after application, it takes about a few hours for the drug to enter the circulation), thus failing to provide an ideal mode of administration.
However, no sufficient studies have been undertaken on the optimum conditions of electrical current application for the administration of a GP IIb / IIIa antagonist by iontophoresis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for transdermal administration of gp iib/iiia antagonist
  • Method for transdermal administration of gp iib/iiia antagonist
  • Method for transdermal administration of gp iib/iiia antagonist

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

[0245] As the device for transdermal administration by iontophoresis, a device comprising of an anode patch and a cathode patch was prepared.

[0246] As illustrated in FIG. 2, the anode patch comprises a foil silver electrode 1, a conductive layer 2 comprising 1.0%(w / w) of an agar gel containing the about 5%(w / w) ion exchange resin cholestyramine, additives (5%(w / w) of urea, 10%(w / w) of proline, 0.1%(w / w) sodium benzoate, 0.03 t(w / w) citric acid) and a thickener(0.25%(w / w) of xanthan gum and 0.25%(w / w) of locust bean gum), a cup-shaped support 3 (inner diameter: about 30 mm, thickness: about 1.5 mm, volume: about 1.3 mL, weight: about 1.3 g) for holding 1 and 2, an adhesive member 4 for affixing the device in position on the skin, and a porous membrane (drug-holding membrane) 5 for holding the drug [Hydrophilic Durapore (TM), Nippon Millipore]. The area of contact surface of the anode patch with the skin is about 9 cm.sup.2.

[0247] The cathode patch was comprising a print silver / silver...

reference example 2

[0249] Except that 609 .mu.g of the compound synthesized in Production Example was applied to the drug-holding membrane, the transdermal administration of the compound by iontophoresis and serial determination of its serum concentration were carried out in otherwise the same manner as in Reference Example 1.

reference example 3

[0250] Except that 2494 .mu.g of the compound synthesized in Production Example 1 was applied to the drug-holding membrane, the transdermal administration of the compound by iontophoresis and serial determination of its serum concentration were carried out in otherwise the same manner as in Reference Example 1.

[0251] The time course of the serum concentration of the compound synthesized in Production Example 1 following the commencement of administration in each of Reference Examples 1 to 3 is presented in FIG. 3. The results indicated that current-responsive blood concentrations were obtained. As shown in FIG. 3, the compound was absorbed through the skin in relation to the electrical current applied, resulting in an increasing serum concentration of the compound. Furthermore, the absorption by the iontophoresis of the compound was dose-dependent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

A method for transdermal administration of a GP IIb / IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density. The method insures excellent pharmacologic efficacy with a low risk for side effects in the prevention and therapy of (1) angina pectoris, (2) unstable angina and (3) ischemic complications and coronary arterial reocclusion or restenosis associated with PTCA or coronary thrombolysis.

Description

[0001] The present invention relates to a method for transdermal administration of a GP IIb / IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density.[0002] In recent years a variety of compounds designed to produce antithrombotic effects through the inhibition of platelet aggregation by competitive antagonism against GP IIb / IIIa, one of the platelet receptors, have been synthesized for possible application to the prophylaxis and therapy of (1) angina pectoris, (2) unstable angina and (3) reobstruction and restenosis of coronary arteries after PTCA (percutaneous transluminal coronary angioplasty) or coronary thrombolysis, among other applications. Particularly among GP IIb / IIIa antagonists comprising 2-piperazinone-1-acetic acid derivatives, compounds having high anti-platelet aggregation activity have been discovered (e.g. JP-A-25285 / 1994, JP-A-316059). However, generally the following three problems have been p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/495A61N1/30
CPCA61K31/495A61N1/30
Inventor IGA, KATSUMIMATSUMOTO, YUKIHIRO
Owner HISAMITSU PHARM CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products